Vertex Pharmaceuticals Incorporated · VRTX · Next earnings

Vertex Pharmaceuticals Incorporated reports Monday, Nov 2, 2026

VRTX reports after market close with consensus EPS at $4.77 and revenue at $3.41B. Last quarter: Vertex Q1: Revenue Up 8%, Renal Pipeline Advances, Guidance Reaffirmed

Reports After market close43 days awayDate estimated Healthcare

What the street expects

Consensus for the coming report
Consensus EPS $4.77 Calendar consensus
Consensus revenue $3.41B Calendar consensus
Report date Nov 2, 2026 Monday, date estimated
Session After market close 43 days away

Where VRTX left off: FY2026 Q1

Full report

Vertex Q1: Revenue Up 8%, Renal Pipeline Advances, Guidance Reaffirmed

EPS surprise +5.4% Reported $4.47 vs $4.24
Revenue surprise -0.2% Reported $2.99B vs $2.99B
Stock move -1.3% Event window
Subsequent drift +0.9% Up to 20 sessions

Full-year 2026 revenue guidance of $12.95–$13.10 billion (8–9% growth) was reaffirmed, as was the expectation for non-CF revenue exceeding $500 million and non-GAAP operating expenses of $5.65–$5.75 billion. Guidance sentiment was maintained with no upward or downward revision.

What to watch on the call

Carried forward from the last transcript

Risks management flagged

  • Regulatory approval timelines for renal assets (Povi, enaxaplin, VX-407) remain uncertain
  • Safety monitoring for Povi, particularly hypogammaglobulinemia and infection risk, could affect launch timing
  • VX-522 discontinuation highlights delivery challenges for nucleic-acid-based therapies
  • Gross-to-net normalization for GERNAVICS could pressure near-term reported revenue
  • Competitive pressure in both CF and emerging renal markets

Questions analysts left open

  • What enrollment criteria and efficacy thresholds are needed for enaxaplin AMPLITUDE to justify further advancement?
  • How will Povi differentiate against competitor Otsuka and other B-cell therapies in renal and autoimmune markets?
  • Timing and magnitude of eGFR data for Povi relative to competitors
  • Prescription volume versus revenue for GERNAVICS and impact of inventory destocking
  • Impact of VX-522 discontinuation on the broader CF pipeline and delivery technology strategy

Ask FN2 about VRTX next report

Transcript, numbers and history already loaded
What should I watch for in VRTX's next earnings report?How did VRTX guide last quarter, and is consensus above or below that?Give me the bull and bear case going into VRTX earnings.

Free account. Your question opens in FN2 with this report's transcript and numbers attached.

Get the VRTX recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Recent VRTX quarters

All VRTX earnings
-1.3%FY2026 Q1

Sources

  1. FN2 corporate events calendar, resolved from the earnings calendar feed
  2. FN2 earnings calendar analyst consensus
  3. Earnings call transcript analysis, FY2026 Q1

Methodology

The report date comes from FN2's resolved corporate-events calendar and is marked estimated until the company confirms it. Consensus figures are the calendar's latest analyst estimates for the fiscal period and are not an FN2 forecast.

Risks and open questions are carried forward verbatim from FN2's structured analysis of the previous earnings call. Missing values stay missing and are never estimated.

By FN2 Research · Updated . For educational purposes only; not investment advice.